Drug intelligence / Profile preview

BY006

Development stage: Preclinical
Lead developer: Beyang Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

BY006 is an orally bioavailable small molecule drug candidate being developed by Beyang Therapeutics for the treatment of Type 1 and Type 2 diabetes. Discovered using the company's proprietary ExCEED drug discovery platform, which leverages computational modeling and artificial intelligence, BY006 is designed to promote the regeneration of pancreatic β-cells. This mechanism aims to restore insulin production capacity, potentially addressing the underlying pathology of insulin deficiency in diabetic patients. As of early 2024, the candidate is in the preclinical stage of development.

Beyond the preview

Go deeper on BY006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BY006.

Explore the full profile